alpha-hydroxyglutarate has been researched along with Leukemia, Myeloid, Acute in 35 studies
2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.
2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Excerpt | Relevance | Reference |
---|---|---|
"We studied whether 2HG measurements in acute myeloid leukemia (AML) patients correlate with IDH mutations, and whether diagnostic or remission 2HG measurements predict survival." | 2.78 | Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. ( Abdel-Wahab, O; Agresta, S; Carroll, M; DiNardo, CD; Fernandez, HF; Lazarus, HM; Levine, RL; Litzow, MR; Loren, AW; Luger, SM; Margolis, DJ; Paietta, E; Patel, JP; Perl, AE; Propert, KJ; Rowe, JM; Straley, KS; Sun, Z; Tallman, MS; Yen, K, 2013) |
"Glutaminase (GLS) is a mitochondrial enzyme that catalyzes the conversion of Gln to glutamate." | 1.43 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016) |
" Inhibition of glutaminase by allosteric GLS inhibitor bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide or by novel, potent, orally bioavailable GLS inhibitor CB-839 reduced intracellular glutamate levels and inhibited growth of AML cells." | 1.43 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016) |
"We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD)." | 1.40 | Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. ( Auger, N; Barouki, R; Bennaceur-Griscelli, A; Bernard, OA; Berthon, C; Caillot, D; Chachaty, E; Courtier, MH; de Botton, S; Dombret, H; Forget, S; Griscelli, F; Janin, M; Koscielny, S; Leclercq, E; Micol, JB; Mylonas, E; Ottolenghi, C; Pautas, C; Penard-Lacronique, V; Preudhomme, C; Quivoron, C; Rabier, D; Renneville, A; Saada, V; Scourzic, L; Solary, E, 2014) |
"Acute leukemias are clonal disorders of hematopoiesis wherein a leukemic stem cell (LSC) acquires mutations that confer the capacity for unlimited self-renewal, impaired hematopoietic differentiation, and enhanced proliferation to the leukemic clone." | 1.36 | Metabolism and the leukemic stem cell. ( Abdel-Wahab, O; Levine, RL, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 32 (91.43) | 24.3611 |
2020's | 3 (8.57) | 2.80 |
Authors | Studies |
---|---|
Lyu, J | 1 |
Liu, Y | 1 |
Gong, L | 1 |
Chen, M | 1 |
Madanat, YF | 1 |
Zhang, Y | 1 |
Cai, F | 1 |
Gu, Z | 1 |
Cao, H | 1 |
Kaphle, P | 1 |
Kim, YJ | 1 |
Kalkan, FN | 1 |
Stephens, H | 1 |
Dickerson, KE | 1 |
Ni, M | 1 |
Chen, W | 1 |
Patel, P | 1 |
Mims, AS | 1 |
Borate, U | 1 |
Burd, A | 1 |
Cai, SF | 1 |
Yin, CC | 1 |
You, MJ | 1 |
Chung, SS | 1 |
Collins, RH | 1 |
DeBerardinis, RJ | 1 |
Liu, X | 1 |
Xu, J | 1 |
Thomas, D | 2 |
Wu, M | 1 |
Nakauchi, Y | 1 |
Zheng, M | 1 |
Thompson-Peach, CAL | 1 |
Lim, K | 1 |
Landberg, N | 1 |
Köhnke, T | 1 |
Robinson, N | 1 |
Kaur, S | 1 |
Kutyna, M | 1 |
Stafford, M | 1 |
Hiwase, D | 1 |
Reinisch, A | 1 |
Peltz, G | 1 |
Majeti, R | 3 |
Gunn, K | 1 |
Myllykoski, M | 1 |
Cao, JZ | 1 |
Ahmed, M | 1 |
Huang, B | 1 |
Rouaisnel, B | 1 |
Diplas, BH | 1 |
Levitt, MM | 1 |
Looper, R | 1 |
Doench, JG | 1 |
Ligon, KL | 1 |
Kornblum, HI | 1 |
McBrayer, SK | 1 |
Yan, H | 1 |
Duy, C | 1 |
Godley, LA | 2 |
Koivunen, P | 1 |
Losman, JA | 1 |
Dang, L | 4 |
Su, SM | 4 |
Showalter, MR | 1 |
Hatakeyama, J | 1 |
Cajka, T | 1 |
VanderVorst, K | 1 |
Carraway, KL | 1 |
Fiehn, O | 1 |
Jones, PM | 1 |
Boriack, R | 1 |
Struys, EA | 4 |
Rakheja, D | 1 |
Montalban-Bravo, G | 1 |
DiNardo, CD | 2 |
Lin, P | 1 |
Luo, Y | 1 |
Zhu, S | 1 |
Maggio, D | 1 |
Yang, H | 3 |
Hu, C | 1 |
Wang, J | 1 |
Zhang, H | 1 |
Ren, Y | 1 |
Zhou, X | 1 |
Mei, C | 1 |
Ma, L | 1 |
Xu, W | 1 |
Ye, L | 1 |
Zhuang, Z | 1 |
Jin, J | 2 |
Tong, H | 1 |
Bories, PN | 1 |
Nakib, S | 1 |
Cynober, L | 1 |
Alary, AS | 1 |
Coude, MM | 1 |
Chevillon, F | 1 |
Tamburini, J | 1 |
Birsen, R | 1 |
Kosmider, O | 1 |
Bouscary, D | 1 |
Brunner, AM | 1 |
Neuberg, DS | 1 |
Wander, SA | 1 |
Sadrzadeh, H | 1 |
Ballen, KK | 1 |
Amrein, PC | 1 |
Attar, E | 1 |
Hobbs, GS | 1 |
Chen, YB | 1 |
Perry, A | 1 |
Connolly, C | 1 |
Joseph, C | 1 |
Burke, M | 1 |
Ramos, A | 1 |
Galinsky, I | 1 |
Yen, K | 4 |
Straley, K | 3 |
Agresta, S | 3 |
Adamia, S | 1 |
Borger, DR | 1 |
Iafrate, A | 1 |
Graubert, TA | 1 |
Stone, RM | 1 |
Fathi, AT | 1 |
Wang, F | 1 |
Travins, J | 1 |
DeLaBarre, B | 1 |
Penard-Lacronique, V | 3 |
Schalm, S | 1 |
Hansen, E | 1 |
Kernytsky, A | 1 |
Liu, W | 1 |
Gliser, C | 1 |
Gross, S | 2 |
Artin, E | 1 |
Saada, V | 3 |
Mylonas, E | 2 |
Quivoron, C | 3 |
Popovici-Muller, J | 1 |
Saunders, JO | 1 |
Salituro, FG | 1 |
Yan, S | 1 |
Murray, S | 1 |
Wei, W | 1 |
Gao, Y | 1 |
Dorsch, M | 1 |
Schenkein, DP | 2 |
Biller, SA | 1 |
de Botton, S | 3 |
Yen, KE | 1 |
Propert, KJ | 1 |
Loren, AW | 1 |
Paietta, E | 1 |
Sun, Z | 1 |
Levine, RL | 4 |
Straley, KS | 1 |
Patel, JP | 1 |
Abdel-Wahab, O | 4 |
Perl, AE | 2 |
Litzow, MR | 1 |
Rowe, JM | 1 |
Lazarus, HM | 1 |
Fernandez, HF | 1 |
Margolis, DJ | 1 |
Tallman, MS | 1 |
Luger, SM | 1 |
Carroll, M | 2 |
Guilhamon, P | 1 |
Eskandarpour, M | 1 |
Halai, D | 1 |
Wilson, GA | 1 |
Feber, A | 1 |
Teschendorff, AE | 1 |
Gomez, V | 1 |
Hergovich, A | 1 |
Tirabosco, R | 1 |
Fernanda Amary, M | 1 |
Baumhoer, D | 1 |
Jundt, G | 1 |
Ross, MT | 1 |
Flanagan, AM | 1 |
Beck, S | 1 |
Wang, JH | 1 |
Chen, WL | 1 |
Li, JM | 1 |
Wu, SF | 1 |
Chen, TL | 1 |
Zhu, YM | 1 |
Zhang, WN | 1 |
Li, Y | 2 |
Qiu, YP | 1 |
Zhao, AH | 1 |
Mi, JQ | 1 |
Wang, YG | 1 |
Ma, QL | 1 |
Huang, H | 1 |
Wu, DP | 1 |
Wang, QR | 1 |
Yan, XJ | 1 |
Yan, JS | 1 |
Li, JY | 1 |
Wang, S | 1 |
Huang, XJ | 1 |
Wang, BS | 1 |
Jia, W | 1 |
Shen, Y | 1 |
Chen, Z | 1 |
Chen, SJ | 1 |
Janin, M | 1 |
Micol, JB | 1 |
Renneville, A | 1 |
Koscielny, S | 1 |
Scourzic, L | 1 |
Forget, S | 1 |
Pautas, C | 1 |
Caillot, D | 1 |
Preudhomme, C | 1 |
Dombret, H | 1 |
Berthon, C | 1 |
Barouki, R | 1 |
Rabier, D | 1 |
Auger, N | 1 |
Griscelli, F | 1 |
Chachaty, E | 1 |
Leclercq, E | 1 |
Courtier, MH | 1 |
Bennaceur-Griscelli, A | 1 |
Solary, E | 1 |
Bernard, OA | 1 |
Ottolenghi, C | 1 |
Wiseman, DH | 2 |
Small, HF | 1 |
Wilks, DP | 2 |
Waddell, ID | 1 |
Dennis, MW | 2 |
Ogilvie, DJ | 1 |
Somervaille, TC | 2 |
Chan, SM | 2 |
Corces-Zimmerman, MR | 1 |
Xavy, S | 1 |
Rastogi, S | 1 |
Hong, WJ | 1 |
Zhao, F | 1 |
Medeiros, BC | 2 |
Tyvoll, DA | 1 |
Clark, CI | 1 |
Jansen, EE | 2 |
Salomons, GS | 1 |
Balss, J | 2 |
Thiede, C | 2 |
Bochtler, T | 2 |
Okun, JG | 3 |
Saadati, M | 1 |
Benner, A | 1 |
Pusch, S | 3 |
Ehninger, G | 1 |
Schaich, M | 1 |
Ho, AD | 3 |
von Deimling, A | 4 |
Krämer, A | 4 |
Heilig, CE | 1 |
Attar, EC | 1 |
Chaturvedi, A | 2 |
Araujo Cruz, MM | 1 |
Jyotsana, N | 1 |
Sharma, A | 2 |
Goparaju, R | 2 |
Schwarzer, A | 1 |
Görlich, K | 1 |
Schottmann, R | 1 |
Rohde, C | 1 |
Müller-Tidow, C | 1 |
Geffers, R | 2 |
Göhring, G | 1 |
Ganser, A | 2 |
Thol, F | 2 |
Heuser, M | 2 |
Poinsignon, V | 1 |
Mercier, L | 1 |
Nakabayashi, K | 1 |
David, MD | 1 |
Lalli, A | 1 |
Broutin, S | 2 |
Paci, A | 2 |
Kingsbury, JM | 1 |
Shamaprasad, N | 1 |
Billmyre, RB | 1 |
Heitman, J | 1 |
Cardenas, ME | 1 |
Chen, JY | 1 |
Lai, YS | 1 |
Tsai, HJ | 1 |
Kuo, CC | 1 |
Yen, BL | 1 |
Yeh, SP | 1 |
Sun, HS | 1 |
Hung, WC | 1 |
Matre, P | 1 |
Velez, J | 1 |
Jacamo, R | 1 |
Qi, Y | 1 |
Su, X | 2 |
Cai, T | 1 |
Lodi, A | 1 |
Sweeney, SR | 1 |
Ma, H | 1 |
Davis, RE | 1 |
Baran, N | 1 |
Haferlach, T | 1 |
Flores, ER | 1 |
Gonzalez, D | 1 |
Konoplev, S | 1 |
Samudio, I | 1 |
DiNardo, C | 1 |
Schimmer, AD | 1 |
Li, W | 1 |
Wang, T | 1 |
Tiziani, S | 1 |
Konopleva, M | 1 |
Lemonnier, F | 1 |
Cairns, RA | 2 |
Inoue, S | 1 |
Li, WY | 1 |
Dupuy, A | 1 |
Martin, N | 1 |
Fataccioli, V | 1 |
Pelletier, R | 1 |
Wakeham, A | 1 |
Snow, BE | 1 |
de Leval, L | 1 |
Pujals, A | 1 |
Haioun, C | 1 |
Tobin, ER | 1 |
Narayanaswamy, R | 1 |
Jin, S | 2 |
Gaulard, P | 1 |
Mak, TW | 2 |
Herbst, L | 1 |
Klett, L | 1 |
Stichel, D | 1 |
Kaulfuss, S | 1 |
Panknin, O | 1 |
Zimmermann, K | 1 |
Toschi, L | 1 |
Neuhaus, R | 1 |
Haegebarth, A | 1 |
Rehwinkel, H | 1 |
Hess-Stumpp, H | 1 |
Bauser, M | 1 |
Bakkali, A | 1 |
Araujo-Cruz, MM | 1 |
Gabdoulline, R | 1 |
Rippe, K | 1 |
Maxmen, A | 1 |
Minden, MD | 1 |
Driggers, EM | 1 |
Bittinger, MA | 1 |
Jang, HG | 1 |
Sasaki, M | 1 |
Fantin, VR | 2 |
Ward, PS | 1 |
Patel, J | 1 |
Wise, DR | 1 |
Bennett, BD | 1 |
Coller, HA | 1 |
Cross, JR | 1 |
Hedvat, CV | 1 |
Rabinowitz, JD | 1 |
Sharp, KA | 1 |
Thompson, CB | 1 |
Sellner, L | 1 |
Capper, D | 1 |
Meyer, J | 1 |
Langhans, CD | 2 |
Hartog, CM | 1 |
Pfeifer, H | 1 |
Serve, H | 1 |
Bhagwat, N | 1 |
Pollyea, DA | 1 |
Kohrt, HE | 1 |
Zhang, B | 1 |
Zehnder, J | 1 |
Schenkein, D | 1 |
Fantin, V | 1 |
Vasanthakumar, A | 1 |
Levine, R | 1 |
Beck, AC | 1 |
Herold-Mende, C | 1 |
Buckel, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prevalence, Correlation With Other Mutant Genes and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia. The European IDH Research Alliance[NCT04369287] | 654 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
Article | Year |
---|---|
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Topics: Acetamides; Antineoplastic Agents; Benzeneacetamides; Benzimidazoles; Biomarkers, Tumor; Drug Discov | 2017 |
The role of IDH mutations in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Enzyme Inhibitors; Epigenesis, Genetic; Glutarates; Humans; Isocitr | 2018 |
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Topics: Bile Duct Neoplasms; Bone Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Chondrosa | 2013 |
IDH mutations in cancer and progress toward development of targeted therapeutics.
Topics: Carcinogenesis; Clinical Trials as Topic; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrog | 2016 |
3 trials available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
Article | Year |
---|---|
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; DNA Mutational Analysis; Female; Follow-Up Studies; Glutarates; Humans; Isocitrat | 2013 |
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Topics: China; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Glutara | 2013 |
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Biomarkers, Tumor; Cytogenetic Analysis; Female; Follow-Up Studies; Glutarates; H | 2016 |
28 other studies available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
Article | Year |
---|---|
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
Topics: Amino Acids; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; NADP | 2023 |
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Topics: Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation | 2023 |
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Topics: Cell Transformation, Neoplastic; DNA Methylation; Glioma; Glutarates; Histone Demethylases; Histones | 2023 |
Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Topics: Biotransformation; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myelo | 2017 |
Measurement of Oncometabolites D-2-Hydroxyglutaric Acid and L-2-Hydroxyglutaric Acid.
Topics: Biomarkers, Tumor; Chromatography, Liquid; Glutarates; Humans; Leukemia, Myeloid, Acute; Stereoisome | 2017 |
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Cohort Studies; Female; | 2018 |
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia.
Topics: Blood Chemical Analysis; Glutarates; Humans; Leukemia, Myeloid, Acute | 2019 |
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; F | 2019 |
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Topics: Allosteric Site; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell | 2013 |
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Topics: Adult; Aged; Area Under Curve; Biomarkers, Tumor; Female; France; Glutarates; Humans; Isocitrate Deh | 2014 |
Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.
Topics: Acute Kidney Injury; Biomarkers, Tumor; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel | 2014 |
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm | 2015 |
Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.
Topics: Gene Frequency; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Po | 2015 |
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
Topics: Animals; Clone Cells; Glutarates; Heterografts; Homeodomain Proteins; Humans; Isocitrate Dehydrogena | 2016 |
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Chromatography, Liquid; Glutarates; Humans; Isocitrate Dehydrog | 2016 |
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Topics: Aldehyde Dehydrogenase; Alleles; Cell Line, Tumor; DNA, Mitochondrial; Glioma; Glutarates; Humans; I | 2016 |
The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Topics: Complement C5a; Gene Expression Regulation, Leukemic; Glutarates; Humans; Interleukin-6; Interleukin | 2016 |
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Topics: Antineoplastic Agents; Apoptosis; Benzeneacetamides; Cell Differentiation; Cell Proliferation; Energ | 2016 |
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
Topics: Animals; Biomarkers, Tumor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genotype; Glutar | 2016 |
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; DNA Methylation | 2017 |
Cancers converge at 2-HG.
Topics: Brain Neoplasms; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; R | 2010 |
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Topics: Catalysis; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myeloid, Acut | 2010 |
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Topics: Cell Proliferation; Glutarates; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; L | 2010 |
Metabolism and the leukemic stem cell.
Topics: Animals; Cholecalciferol; Glutarates; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hypoxia-Induc | 2010 |
Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.
Topics: Adult; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel | 2010 |
Metabolic syndromes and malignant transformation: where the twain shall meet.
Topics: Cell Transformation, Neoplastic; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Mye | 2010 |
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
Topics: 5-Methylcytosine; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leu | 2013 |
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Topics: Alcohol Oxidoreductases; Biomarkers, Tumor; Enzyme Assays; Glutarates; Humans; Isocitrate Dehydrogen | 2012 |